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It is a challenge to select the right target to treat conditions without 
affecting non-diseased cells. Cancer belongs to the top 10 of the causes of 
death in the world and it remains difficult to treat. Amongst cancer 
emerging targets, silent information regulator 1 (sirt1) – a histone 
deacetylase – has shown many roles in cancer, ageing and metabolism. Here 
we report novel SIRT1 ligands that bind and modulate the activity of SIRT1 
within cells and enhances its enzymatic activity. We developed a modified 
aptamer capable of binding to and forming a complex with SIRT1. Our 
ligands are aptamers, they can be made of DNA or RNA oligonucleotides, 
their binding domain can recognise a target with very high affinity and 
specificity. We used the Systematic Evolution of Ligands by Exponential 
enrichment (SELEX) technique to develop circular and linear aptamers 
selectively binding to SIRT1. Cellular consequences of the interaction were 
monitored by fluorescence microscopy, cell viability assay, stability and 
enzymatic assays. Our results indicate that from our pool of aptamers, 
circular AC3 penetrates cancerous cells and is recruited to modulate the 
SIRT1 activity.  This modulation of SIRT1 resulted in anticancer activity on 
different cancer cell lines. Furthermore, this modified aptamer showed no 
toxicity on one non-cancerous cell line and was stable in human plasma. We 
have demonstrated that aptamers are efficient tools for localisation of 
internal cell targets, and in this particular case, anticancer activity through 
modula-tion of SIRT1. 
1 Introduction 
Histone deacetylases (HDACs) remove the acetyl group from the ε-
amino lysine residues on histones, making the interaction between 
histones and DNA stronger. This tight interaction reduces the 
chances of RNA polymerase contacting DNA1-3. This interaction 
regulates gene expression affecting the development of multiple 
diseases including cancer2. Human HDACs are classified into four 
classes: I, II III and IV3. The class III enzymes are known as Sirtuins4, 
these enzymes are NAD+-dependent consisting of SIRT1 to SIRT75, 6. 
SIRT1 is the most studied, it can be present in the nucleus or the 
cytoplasm depending on the cell type or tissue evaluated7. While the 
functions of SIRT1 are still largely unknown, a link between SIRT1 
activity and the metabolic status of the cell has been suggested7. 
SIRT1 targets multiple proteins such as p53, p73, E2F, HIC1 and Ku70, 
all of which are responsible for major cellular processes8. SIRT1 
expression has been shown to be significantly elevated in various 
cancers6, 9-12. However, the mechanism of dysregulation of SIRT1 is 
still unclear. Overexpression of SIRT1 could be a consequence of 
cancer rather than a cause2. Under physiological conditions in 
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response to cellular stress or to DNA damage, SIRT1 appears to 
promote cell survival via cell cycle arrest, DNA repair, or inhibition of 
apoptosis. In case of persistent stress signal or significantly high 
levels of cellular damage SIRT1 induces cell senescence2.  
Macromolecules, like DNA, can offer a more selective and effective 
approach in inhibition of enzymes. Nucleic acid-based aptamers rely 
on their 3D structure to recognise and bind their selective targets 
through a combination of quadruplexes, triplexes, pseudoknots, 
hairpins, bulges, loops and stems13. Aptamers have many advantages 
over small molecules and to a certain extent over antibodies, for 
example, they present high specificity and affinity, present low 
immunogenicity14, 15, and can be selected in vitro with reduced costs. 
Aptamers are stable upon modifications presenting a longer half-life 
while avoiding bio-transformation and have a wide range of potential 
targets16. The approach of combinatorial chemistry is used to 
generate and select aptamers, they are generally obtained through a 
process known as SELEX, where a library of oligonucleotides is 
incubated with the target. The bound sequences are separated from 
unbound ones, and they are subsequently amplified for further 
iterative cycles. After 8-12 rounds a small number of sequences are 
obtained and taken for further studies. They have applications in the 
environmental, pharmaceutical and analytical industries17, 18. Nucleic 
acids are prone to degradation by nucleases. Due to this, linear 
aptamers present stability issues in vivo. Chemically modified 
counterparts have shown improvements, for example, 3′-end 
capping with inverted thymidine19, biotin conjugates20, 2′-fluoro (2′-
F) or 2′-amino (2′-NH2) ribose groups21, phosphodiester linkage of 
DNA replaced with methylphosphonate or phosphorothioate 
analogue22, oligonucleotide phosphodiester linkage replaced with 
triazole linkages23, L-DNA24, 5′-end with cholesterol25, dialkyls lipids26 
PEGylation27 and base modifications like phosphorodithioate (PS2) 
substitution28 or 5-(N-benzylcarboxyamide)-2′-deoxyuridine 
modification that produces Slow Off-rate Modified Aptamers 
(SOMAmers)29. Locked nucleic acids are analogues of ribonucleotides 
with a methylene linkage between 2′-O and 4′-C of the sugar ring; 
they are resistant to nuclease activity30. Their secondary structure 
which is responsible for functionality might be affected due to post-
selection modifications. 
The SELEX methodology can be used employing a variety of methods, 
such as capillary electrophoresis (CE-SELEX)31, microfluidic (M-
SELEX)32, cell (cell-SELEX)33, in vivo from a tumour inside an animal (in 
vivo-SELEX)34 and high-throughput sequencing (HTS-SELEX)35. 
Molecular entrance into the cells is favoured by non-charged 
molecules, hence many aptamers are designed for extracellular 
targets19, 36, 37. Circular nucleic acids have also shown to be stable 
since they have no 3’ or 5’ ends exposed to be acted upon by 
exonuclease digestion19. Circularisation of aptamers is an attractive 
alternative to chemical modification for improving aptamer stability 
as well as assisting with aptamer internalisation through the cell 
membrane38. These aptamers can demonstrate good stability and 
internalisation   potential. Circularisation of aptamers permits the 
use of unmodified nucleotides thus avoiding potential toxicity 
associated with chemical modification.  
SIRT1 was chosen for its dual activity during cell cycle and its 
potential role in carcinogenesis. Our initial hypothesis stipulated that 
a circular aptamer would be able to penetrate a living cell due to its 
non-charged conformation and this could be monitored via 
fluorescence microscopy. Our aptamer selection used a DNA library 
in circular and linear forms. The circular selection produced an 
aptamer capable of selective binding to SIRT1 modulating its activity 
with further implications in biological activity studies.  
2 Experimental 
2.1 Materials and methods 
Chemicals were purchased from ThermoFisher Scientific, Sigma-
Aldrich or SLS (Scientific Laboratory Supplies). A549, MCF7, MDA-
MB468 and U2OS cells were purchased from Sigma-Aldrich. Caco-2, 
Beas2B and HepG2 were purchased from the American Type Culture 
Collection (ATCC). BEGM Bulletkit was purchased from Lonza. 
Recombinant human SIRT1-GST-tagged [SIRT1-462H] was purchased 
from Creative BioMart. PreScission Protease on-column GSTrap FF 
and NHS-HP SpinTrap column were purchased from GE HealthCare. 
DNA library 5ˋ-TTCGGAAGAGATGGCGAC- N40-
CGAGCTGATCCTGATGGAA-3ˋ was purchased from TriLink Bio 
Technologies. Phosphorylation reaction kit (EK00310), T4DNA 
(EL0012) and Exonuclease I (EN0581) were purchased from 
ThermoFisher Scientific. BAS-P1, BAS-P3 and BAS-P3- no tail primers 
(BAS-P1: 5'-TTCGGAAGAGATGGCGAC-3',  
BAS-P3: 5'-ATGTCGTGCGTGCTA-SP18-TTCCATCAGGATCAGCTCG-3', 
BASP3-notail: 5'-TTCCATCAGGATCAGCTCG-3'),  C1: 5’-
TTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAAC-3’; C2:5’-
TTCGGAAGAGATGGCGAC 
TTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAAC 
CGAGCTGATCCTGATGGAA-3’; AC3: 5’- 
CGAGTGGGTTACATCGAAACTGGATCTCAACAGCGGTAAC-3’; C4:5’-
TTCGGAAGAGATGGCGAC 
CGAGTGGGTTACATCGAAACTGGATCTCAACAGCGGTAAC 
CGAGCTGATCCTGATGGAA-3’; C5: 5’- 
CACTCCCTCTGCGTGCGAATTTTGCCTATGGCGCATATTC-3’; C6:5’-
TTCGGAAGAGATGGCGAC 
CACTCCCTCTGCGTGCGAATTTTGCCTATGGCGCATATTC 
CGAGCTGATCCTGATGGAA-3’; L1: 5’- 
CGGACTGCAACCTATGCTATCGTTGATGTCTGTCCAAGCA-3’; L2:5’-
TTCGGAAGAGATGGCGAC 
CGGACTGCAACCTATGCTATCGTTGATGTCTGTCCAAGCA 
CGAGCTGATCCTGATGGAA-3’; L3: 5’- 
CACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTA-3’; L4: 5’-
TTCGGAAGAGATGGCGAC 
CACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTA 
CGAGCTGATCCTGATGGAA-3’; and AC3-FAM (5′-CGAG-i6-FAMK-
GGGTTACATCGAAACTGGATCTCAACAGCGGTAAC-3′) were purchased 
from IDTDNA (FAM is an NHS ester);  
Scrambled: 5’- 
ACGCGATACAGTCCTAAGTGGATCAAGTGGCGATACCTGA-3’. 
ISOLATE II PCR and Gel kit, VENT DNA polymerase, Vector Ptz57R/T 
and E. coli DH5α were purchased from Biolabs. Nucleospin® Extract 
II kit and QIAprep Spin Miniprep Kit were purchased from Qiagen. 
Anti-SIRT1 antibody (ab104833) was purchased from Abcam. Alexa 
Fluor 594 goat anti-mouse IgG (AF594, Texas Red dye) was purchased 
from Life Technologies. Clear bottom imaging tissue culture plates 
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were purchased from Corning. Human plasma was purchased from 
Seralab and used immediately.  
2.2 Procedures 
 
2.2.1 SELEX approach. The SELEX approached followed 8 iterative 
cycles for circular aptamers and 12 for linear aptamers (Fig 1). The 
GST-tag from human recombinant SIRT1 was cleaved by PreScission 
Protease on a GSTrap FF column following manufacturer’s 
recommendations (GE Life Sciences, cat 27084301). The extent of 
cleavage of SIRT1 enzyme was determined by SDS- PAGE. SIRT1 (1.0 
mg/ml in coupling buffer) was immobilised in a NHS-HP SpinTrap 
column (1ml) following manufacturer’s recommendations (GE Life 
Sciences, cat 28903128). Modified Library preparation: linear BAS 
library stock (1660pmol, in water) was phosphorylated following 
manufacturer’s recommendations using the phosphorylation 
reaction kit (Fisher Scientific, cat EK00310). The reaction was ethanol 
precipitated and purified by polyacrylamide gel electrophoresis on a 
10 % denaturing gel- 8 M urea. The product was ligated with 4900 U 
T4DNA and followed manufacturer’s recommendations (Fisher 
Scientific, cat EL0012). Circularity of the BAS library was confirmed 
using Exonuclease I digestion by manufacturer’s recommended 
protocol (Fisher Scientific, cat EN0581) with extended incubation 
time to overnight at 37 °C. Selection: For the initial round of 
selection, 100pmol of circularised or linear BAS library were added to 
200 µl of binding buffer (pH 7.4, 100 mM NaCl, 5 mM MgCl2) in the 
column containing SIRT1 and incubated for 2 h at 37 °C. Wash and 
elution buffers were formulated with 5 mM MgCl2 but differing NaCl 
concentrations ranging from 0.15 M to 1.5 M (all at pH 7.4 and 5 mM 
MgCl2: a-150 mM NaCl; b-300 mM NaCl; c-600 mM NaCl; d-900 mM 
NaCl; e-1500 mM NaCl). A wash step with 5 column (1 ml) volumes 
of binding preceded the elution step (solution e). The product 
precipitated from the supernatant with 500 µl of 100 % cold ethanol 
and was spun at 21,000 g at 4 °C for 30 min. The pellet was washed 
with 70 % ethanol and repeated the centrifugation step then dried 
and re-suspended in 20 µl water and set up PCR in 100 µl volumes. 
To determine if the library could bind to the column in absence of 
SIRT1, 1.0ml of BAS library in binding buffer was introduced in the 
column, with an OD260nm: 0.1155. After incubation of 2 hours at 37 
°C, 3 ml were flushed through the column; the eluted was collected 
and the absorbance at 260 nm was recorded. The results showed an 
OD260nm: 0.0339 (equivalent to OD260nm: 0.1017 in 1 ml), 
demonstrating that no association was found between the 
oligonucleotides and the column matrix. Polymerase Chain Reaction 
(PCR): 1 μM of both BAS-P1 and BAS-P3 primers plus recovered 
sequences from the previous step, dissolved in 20 μl were used for 
the of PCR amplification process. The 18 atom hexaethylene-glycol 
spacer in the antisense primer BAS-P3 connects the complementary 
primer region to a 15 nt random sequence helping with strand 
separation of the PCR products by PAGE. The PCR program 20 cycles 
run as: denaturation 95 °C-30 sec, annealing: 50 °C-45 sec and 
extension: 72 °C-10 sec, on a Robo Cycler Gradient 96 (Stratagene). 
The product was purified by urea PAGE and ISOLATE II PCR and Gel 
kit (Bioline BIO52058). In the case of linear selection, the product was 
used straight away. In the case of circular selection, phosphorylation 
and circularisation was performed on the pooled PCR products. 
Around 8 rounds were repeated for all the steps of selection circular 
aptamers. Cloning, plasmid isolation and sequencing: the final 
population of the selection step, dissolved in 2 μl was used as 
template, it was added 200 μM dNTP, 1 μM each of BAS-P1 and 
BASP3-no tail primers, buffer and VENT DNA polymerase. PCR 
products were purified for the cloning using the Nucleospin® Extract 
II kit following manufacturer’s instructions (Clontech, cat 636971). 
The ligation reaction was mixed with 0.52 pmol of purified PCR 
product and added to 6 µl of 5X ligation buffer, 0.17 pmol of Vector 
Ptz57R/T and 3U T4 DNA ligase in a final 30 µl volume, stirred for 5 
min and then kept on 4 °C overnight. E. coli DH5α high efficiency 
competent cells were used for transformation following 
manufacturer’s recommendation. For transformation, 100 μl cell 
cultures were plated onto duplicate LB/100 μg/ml ampicillin 50 
µg/ml/IPTG/X–Gal plates. Colonies were incubated overnight at 37 
°C with gentle shaking, picked and inoculated into LB media 
supplemented with 50 μg/ml ampicillin and incubated overnight at 
37 °C with gentle shaking. QIAprep Spin Miniprep Kit manufacturer’s 
recommendations (Qiagen, cat 27104) were used for plasmid 
preparation, for each clone, 0.6 μg purified plasmid DNA was mixed 
with 20 pmol forward primers in a 100 μl PCR tube. All aptamer 
samples were outsourced for sequencing to Source Bio Science. The 
Data of sequencing were analysed by DNAMAN 5.29 software 
(Lynnon corp).  
 
2.2.2 Cell lines and Cultures. A549, HepG2 and MDA-MB468 cells 
were cultured in RPMI-1640 supplemented with 10 % FBS, 1 % L-
Glutamine and 1 % Penicillin Streptomycin-Amphotericin B. MCF-7, 
U2OS and CaCo-2 cells were cultured in DMEM supplemented with 
10 % FBS, 1 % L-Glutamine and 1% Penicillin-Streptomycin-
Amphotericin B. Beas2B cells were cultured in BEGM. All cells were 
cultured in 75 cm2 flasks and incubated in 5 % CO2/95 % humidified 
air at 37 °C.  
 
2.2.3 In Vitro Cytotoxicity Assay and IC50 determination. Incubation 
at different times: in 96-well plates, 5,000/4,000/3,000 cells of A549, 
MCF7, MDA-MB468, Caco-2, HepG2, U2OS and Beas2B cells were 
seeded in 100μl of complete medium per well for test periods of 24, 
48 and 72 hours respectively. The next day, cells were treated with 
aptamer stocks to achieve a final concentration of 2.5 µM. 
Incubation: in 96-well plates, 5,000 cells of A549, MCF7, MDA-
MB468, Caco-2, HepG2, U2OS and Beas2B cells were seeded in 100μl 
of complete medium per well for a test period of 24 hours. The next 
day, cells were treated with AC3 stock to achieve final concentrations 
between 0.25 - 1.0 µM. The plates were then incubated at 5 % 
CO2/95 % humidified air at 37 °C until the day of assay. MTT [3-[4,5-
dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide] was 
prepared at 3 mg/ml in PBS, 30 μl of this solution was added to each 
well and incubated for 4 hours at 37 °C. Following incubation, liquid 
was removed and 100 μl of DMSO were added to each well with 
lightly shaking for 15 min. The optical density of the solution was read 
at 540 nm and corrected for background absorbance at 690 nm on a 
Multiscan reader. The IC50 determination for AC3 followed the same 
protocol with cells dosed for 72 h at different concentrations: 0.078, 
0.156, 0.312, 0.625, 0.125, 0.25, 0.5 and 1µM for A549, MCF7, MDA-
MB468, Caco-2, HepG2, U2OS and Beas2B respectively, the 
normalised dose response was plotted over log transformed vs AC3 
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concentration and IC50 values were determined using nonlinear 
regression analysis Origin 9.1 (Microcal) with all samples were run in 
duplicate.  
 
2.2.4 Characterisation of SIRT1 and enzyme kinetics. SIRT1 
fluorometric drug discovery kit (Fluor de Lys AK-555, Enzo Life 
Science) was used to study the activity of aptamers at different 
concentrations between 0.2 – 2.0 µM, resveratrol at 200 µM and 
nicotinamide at 200µM, following manufacturer's 
recommendations. Assays were run both with an isolated form of 
SIRT1 in a 96-well plate as well as the native SIRT1 in the different 
cells. Samples were read using filter applicable to excitation 
wavelength of 350-380 nm and emission in the range 450-480 nm on 
a LUMIStar Luminometer Microplate Reader. SIRT1 enzyme activity 
was calculated from normalised data to control (cells + vehicle – 
water).  
 
2.2.5 Characterisation of the SIRT1 Enzyme Interaction using 
Surface Plasmon Resonance. SPR experiments run on ProteOn™ 
XPR36 with a ProteOn™ GLM Sensor Chip (MIB, The University of 
Manchester). The system operated at 25 °C in running buffer (100 
mM NaCl, 5 mM MgCl2, pH 7.4). The sensor chip was conditioned 
using 1M NaCl and 50 mM NaOH for 1 min thrice. A range of protein 
concentrations from 12.5 – 800 nM were tested under different 
injection times and the optimum conditions used were 100µl of 800 
nM SIRT1 perfused over each individual channel at the rate of 25 
µl/min for 60 sec pulse. Aptamers were prepared in the selection 
buffer (PB 100 mM NaCl, 5 mM MgCl2, pH 7.4) at 10 µM and was 
injected at a medium pace over the surface at 25 μl/min. After the 
injection was complete, the complex was washed for an additional 
30 sec with binding buffer. The chip surfaces were regenerated down 
to protein level by applying 1.5 M NaCl, 5 mM MgCl2, pH 7.4 in 30 sec 
pulses. Determination of equilibrium dissociation constant (KD) of the 
aptamer-SIRT1 complex was evaluated using ProteOn Manager™ 
software.  
 
2.2.6 In Vitro Target Recognition and Cellular Uptake. 10,000 Caco-
2, HepG2, U2OS, A549, MCF7, MBA-MB468 and Beas2B cells were 
seeded in 100 μl/well of complete medium in clear bottom imaging 
tissue culture plates for 18 hours. On the next day, cells were treated 
with AC3 as 0.1µM for U2OS, and MDA-MB468, 0.2 µM for MCF-7 
and HepG2, 0.3 µM for A549 and Caco2, and 1 µM to Beas-2b and 
incubated at 5 % CO2/95 % humidified air at 37 °C for 72 hours. At 
the end of the incubation period, the cells were washed three times 
in PBS, fixed for 5 min at room temperature with formalin 4 %, 
washed twice in PBS, then permeabilised by 0.5 % Triton X-100 for 5 
min, washed thrice with PBS; nonspecific binding was blocked with 3 
% FBS for 1 h at room temperature, then the blocking solution was 
removed, 100 μl/well of Anti-SIRT1 antibody 1:500 were added to 
cells and incubated overnight at 4 °C. On the next day, cells were 
washed three times in PBS, and incubated for 2 hours in the dark at 
room temperature with 1:2000 Alexa Fluor 594 goat anti-mouse IgG 
/1 % FBS in PBS, then the cells were washed three times in PBS. Cells 
were treated with 10 µl of PBS containing DAPI, left for 1 hour before 
the microscopic examination and image capture in a Cytation™ 3 Cell 
Imaging Multi-Mode Reader. Fluorescence intensity was measured 
by LUMIStar Luminometer Microplate Reader. Filters were used as: 
GFP filter was used for FAM (carboxyfluorescein, green) exc. 495 nm, 
em. 509 nm; DAPI (4',6-Diamidino-2- Phenylindole-dihydrochloride, 
blue) exc. 359 nm, em. 461 nm and Texas Red (sulforhodamine 101 
acid chloride, red) exc. 596 nm, em. 615 nm. The results represent 
the mean ± SEM of duplicates.  
 
2.2.7 Plasma Stability. 1 μM of AC3 in 90% human plasma in PBS, pH 
7.2 was incubated at simulated body temperature for a series of 
times (0, 15, 30, 60, 120, 240 min and 24 hours) at 5 % CO2/95 % 
humidified air at 37 °C. 100 µl of AC3 in water was incubated at zero 
time and after 24 h as controls. Samples were separated using a 
HiChrom ACE Excel 5 super C18 (150 x 4.6mm) column, using a 50 µl 
injection volume and detecting adsorption at 256 nm. The mobile 
phases used were: A: water (HPLC grade), B: Acetonitrile (HPLC 
grade). The gradient profile 0-10 min B 20 %, 10-15 B 100 %, 14-20 
min B 100 %, 20- 25min B 20%. The flow rate was 1.4 ml/min and 
column temperature was maintained at 37 °C. The HPLC-UV system 
used was Agilent 1260 series system consisting of G1329B ALS, 
G1316A TCC, G1315D DAD VL, and a G1311B Quart Pump.  
 
2.2.8 Statistical Analysis. All statistical analysis were performed 
using Origin 9.1 (Microcal) and/or Excel. Comparison between all 
groups within the same assay were evaluated by one-way ANOVA 
(Origin 9.1). Comparison between the same groups within the same 
assay were evaluated by paired t-test using (IBM SPSS Statistics 20) 
statistical software. The significance was calculated by the ANOVA 
one-way test. Values of p < 0.05 were considered statistically 
significant. 
3 Results and discussion 
Modulation of SIRT1 activity is beneficial against several diseases 
including neurodegeneration, cancer, inflammation and metabolic 
diseases2, 3, 8, 39, 40. This manuscript describes two approaches to 
obtain novel DNA aptamers for selective targeting of intracellular 
SIRT1. Two different types of aptamers, linear and circular were 
compared. A comprehensive set of experiments were performed in 
order to select the optimal sequence from our pool of aptamers. 
As shown in Figure 1, the selection steps involved binding, partition, 
elution, amplification (this section is known as SELEX rounds13) and 
cloning. This is an iterative process and can take up to 20 rounds of 
repeated cycles16, 41-43. 
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 Fig. 1 Workflow representation of the selection process. In the case of the 
circular library, the oligonucleotides were phosphorylated and ligated. In the 
case of the linear library, the oligonucleotides were unmodified. First stage of 
the cycle starts with the SIRT1 interacting with either library. Unbound 
sequences were eluted using different NaCl ionic concentration. The bound 
sequences were then amplified by PCR. In the case of circular library, the 
sequences were phosphorylated and ligated before entering the second 
round. The linear library sequences were used from the purification step after 
the PCR one. Once eight cycles (circular) and twelve (linear) were performed, 
the sequences were cloned, analysed and studied for biological activity. 
 
Enrichment of selective sequences can be monitored after each 
round until a plateau of intensity for each band is reached as shown 
via polyacrylamide gels (Figures 1A and 1B, SI). 
 
3.1 Circularisation and preparation of SIRT1  
 
Aptamers are generally developed through linear selection, in our 
case, for the linear selection, the library was used without any 
modifications. Circular aptamers obtained from a circular library is 
labouring and time consuming, requiring several steps of 
phosphorylation and ligation. A random DNA library contains various 
sequence motifs ranging from 1013 to 1015 in number44 of a central 
random sequence of 20-80 nucleotides with flanking regions of 18-
21 nucleotides that will form the binding site for primers during PCR. 
This randomisation allows a wide diversity of possible sequences. For 
example, four different nucleotides at 40 randomised positions gives 
a theoretical possibility of 1024 different sequences45. Our library 
named BAS has a random sequence of 40 nucleotides with flanking 
primer sequences forming a total of 77 nucleotides. It was used as 
precursor pool for the selection of aptamers for SIRT1. The library 
was 3’-phosphorylated and circularised. Circularisation of all the 
sequences in the library might not be possible, so a mix between 
inter-sequences and intra-sequences might form. To avoid this, the 
circularisation step was performed in a dilute solution to circumvent 
intra-strands association, and a step of gel purification was added 
after the circularisation. Gel assays showed no evidence of double 
aptamer (Figure 2, SI). The circular form of our library was confirmed 
by digesting it with the enzyme Exonuclease I.  
 
Our target enzyme, SIRT1, was commercially obtained and purified 
to remove the GST-tag through cleavage of the GST-tag in a GSTrap 
FF column. The purification stage was evaluated by SDS–PAGE using 
4–20% stacking polyacrylamide gel and stained with Instant Blue 
stain (Figure 3, SI). This purified SIRT1 was later immobilised on a NHS 
HP SpinTrap column before proceeding to the SELEX step.  
 
3.2 SELEX, DNA Cloning and Sequencing 
 
Two pools of ssDNA libraries were employed. One pool was used for 
the linear selection and the second pool was phosphorylated and 
circularised producing the circular library.  
 
Oligonucleotides were dissolved in binding buffer, they interacted 
with the immobilised SIRT1 and any weak interactions were eluted 
by a range of buffers with increasing ionic strength. The buffer 
selection scheme was designed to wash away unbound sequences 
upon different ionic concentrations. This scheme ensures there is an 
enrichment of selective aptamers in direct relation to higher ionic 
strength. Different concentrations of NaCl were used to elute the 
unbound and bound oligonucleotides. A lower concentration of NaCl 
was used to elute unbound sequences and slightly higher ones were 
used to release mildly bound ones. Tightly bound oligonucleotides 
were recovered using a high salt concentration step. Once the 
sequences were recovered, the samples were desalted and amplified 
through PCR. In the case of the circular selection, prior to each new 
cycle, the library was again phosphorylated, circularised and purified. 
 
After eight rounds of selection for the circular aptamer and twelve 
ones for the linear selection of aptamers, the PCR products were 
then cloned and 144 clones (72 for each linear and circular) were 
obtained for consensus sequence family analysis. From them, 50 
complete sequences from each linear and circular set were used in 
class analysis sorted as shown in Table 1. 
 
Table 1 Complete sequences obtained after 8 rounds of selection. 
 
Clone Sequence (5’ → 3’) (N40)@ Frequency 
% 
1# CAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGC 12 
2# TTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAAC 24 
   
3# CGAGTGGGTTACATCGAAACTGGATCTCAACAGCGGTAAC 28 
4# CACTCCCTCTGCGTGCGAATTTTGCCTATGGCGCATATTC 36 
5$ ACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTGCC 18 
6$ CCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCCTGC 14 
7$ CGGACTGCAACCTATGCTATCGTTGATGTCTGTCCAAGCA 38 
8$ CACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTA 30 
Note: @: TTCGGAAGAGATGGCGAC*-N40- CGAGCTGATCCTGATGGAA, primers in red; #: 
circular selection; $: L: linear selection 
 
In Table 1 the clones, without primer sequences, are showed as 
clones 1 to 4 from the circular selection and 5 to 8 from the linear 
selection.  Clones 1, 5 and 6 were removed from further studies as 
the frequency was very low. For our further studies we re-named 
them as C or L denomination for circular or linear and added –P for 
the sequences tested with their primers. Clone 2 became C1, clone 3 
is AC3, clone 4 is C5, clone 7 is L1 and clone 8 is L2.  
 
 3.3 SIRT1 and aptamer interaction 
 
Aptamers are known for selective binding to their targets. Our 
selected aptamers were tested for activation and inhibition activities. 
We monitored the in vitro activity of the aptamers with and without 
the primers (aptamers with and without primers are presented in 
Table 1, SI. Circularity for aptamers is presented in Figure 4, SI).  
 
The Fluor de Lys SIRT1 kit is a fluorescence-based assay, which uses 
a small lysine-acetylated peptide, corresponding to K382 of human 
p53, as a substrate. It has been extensively used in literature to study 
SIRT1 activators and inhibitors. The kit also recommends the use of 
resveratrol as positive control. This polyphenolic compound has been 
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widely used due to its positive stimulation of SIRT1 activity46, 47. The 
assay monitors the fluorescence intensity of the Fluor de Lys de-
acetylated product in a direct linear relationship to its concentration. 
To obtain fold induction values, the results at different 
concentrations of aptamers and resveratrol were normalised to only-
vehicle samples. 
 
The primers are part of the sequence during selection therefore, we 
tested if they had any effect. The aptamers with primers did not 
present any enhanced activity in relation to the counterpart without 
primers, confirming the activity was attributed to the target 
sequence and not due to the primer sequence (expanded results are 
shown Table 2, SI).  
 
Resveratrol is the most widely studied SIRT1 activator, in our studies 
it produced a 2.8 fold activity at 200 µM. Table 2 shows the results 
for the most active aptamers with and without their primer 
sequences. At 0.8 µM, 2.7, 2.7 and 2.9 fold induction activity were 
produced by L3, L3-P and AC3 respectively. These aptamers have 
demonstrated extremely high performance. Though C3-P produced 
a very remarkable fold induction activity, its cell viability was quite 
modest when compared to AC3 alongside the difficulty in producing 
vast quantities for further studies. 
 
Table 2 The fold activity is presented as data normalised with respect to 
buffer. 
Concentration 
µM 
L3 L3-P AC3 C3-P Resv.#
l 
200     2.8 
0.800 2.7 2.7 2.9   
0.400 2.6 2.6 2.7   
0.300*    2.6  
0.200 2.4 2.6 2.6   
0.150    2.6  
0.100 2.2 2.3 2.5   
0.075    2.3  
0.037    2.1  
Note: * C3-P was tested at a different concentration because of a much lower yield than 
the other aptamers, Resv#: resveratrol. p < 0.05. 
 
A time course study up to 45 minutes using the same kit was 
employed to study the behaviour of AC3, C3-P, L3 and L3-P in respect 
to resveratrol, at different concentrations. Our results (Figure 5, SI) 
showed all our aptamers yielded more product than resveratrol at 30 
and 45 minutes of incubation, even at 0.1 µM concentration. 
 
In general SIRT1 allosteric activators decrease the acylated protein 
equilibrium dissociation constant for the substrate48. In a possible 
mechanism of action the aptamer would bind to an allosteric site of 
SIRT1 inducing conformational changes in the substrate binding 
pocket increasing the activity. 
 
Surface Plasmon Resonance (SPR) provides information about the 
interaction of a protein and its substrate (extensive explanation can 
be found in SPR section in SI). L3, L3-P, AC3 and C4 were the best 
performing aptamers in our activity tests therefore they were taken 
for SPR studies. The sensor surface was built upon by immobilisation 
of aptamers on the sensor chip, and SIRT1 was injected at different 
concentrations up to 800 nM. An aptamer level of 1000–1200 RU on 
the sensor surface was maintained during the immobilisation of the 
aptamer. SPR sensorgram results are shown in Table 3 (Figures 6 A 
to D, SI). Our results revealed a very tight and stable binding 
behaviour of SIRT1 enzyme to AC3 presenting an equilibrium 
dissociation constant (KD) of 0.27± 0.01 nM.  
 
Table 3 Association binding parameters resulting from the analysis of the 
Surface Plasmon Resonance data for the interaction between the selected 
aptamers and the SIRT1 enzyme. 
Aptamer KD (nM) 
AC3 0.27 ± 0.01 
C3-P 0.66 ± 0.01 
L3 0.48 ± 0.01 
L3-P 1.03 ± 0.01 
 
The SPR data have demonstrated the high affinity of AC3 for SIRT1, 
with KD values in the sub-nanomolar range. These data are consistent 
with published results of other aptamers including aptamers against 
thrombin (KD= 25–200 nmol/l)49, PSMA (KD=2 nmol/l)50, tenascin C 
(KD = 5 nmol/l)51 and c-di-GMP Vibrio cholerae (KD in the range  10 
pM)52. 
 
3.4 Cell viability  
 
L3, L3-P, AC3 and C3-P were moved forward for studies on a range of 
different cancer cell lines relevant to the most common types of 
cancer. The selected cancer cell lines presented different expression 
patterns of SIRT1. TBHP (tert-butyl hydroperoxide (tBuOOH), an 
organic peroxide was used as positive control as it is widely known 
to produce cell stress followed by apoptosis53. Results, as presented 
in Figure 2, demonstrate excellent activity by the aptamer AC3. 
 
The human osteosarcoma U2OS cell line is an example of SIRT1 
overexpression54-56.  L3 and L3-P were the least active with their 
toxicity remaining stable. C3-P and AC3 were more toxic to U2OS, 
especially AC3.  
 
SIRT1 expression on breast cancer cells appears to be mixed, with 
over57, 58 and under expression59, 60. In this work we employed two 
breast cancer cell lines, MCF-7 as breast cancer cell line oestrogen 
positive61 and MDA-MB468 as oestrogen negative58, 62. Aptamers L3 
and L3-P were the least active on MCF7 though their toxicity 
increased towards the 72 hours period of incubation.  AC3 was the 
most toxic to the cells. On MDA-MB468, L3-P had no effect on this 
cell line. L3, AC3 and C3-P showed an increase activity on this cell line, 
especially AC3. 
 
HepG2 is a hepatocellular cancer cell line documented to 
overexpress SIRT175. In HepG2 all aptamers showed activity on this 
cell line, especially AC3. 
 
Beas2B cells are immortalised human bronchial epithelium normal 
cells63, 64. No over or under expression of SIRT1 has been reported in 
this cell line. The aptamers did not affect significantly this cell line; 
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implying there is a relationship between SIRT1 stimulation and 
cancer death.  
 
SIRT1 expression appears to be decreased in human ColoRectal 
Cancer (CRC) including Caco-265. The opposite is found on human 
non-small cell lung cancer cell lines such as A54966. On Caco-2 L3, AC3 
and C3-P were toxic to the cells. On A549, all aptamers were toxic to 
A549 cells mainly AC3.  
 
As shown in Figure 2, at 72 hours AC3 left 6.3, 17.6, 20.1, 7.1, 21.6, 
7.6 and 88.2 % of viable cells for U2OS, MCF7, MDA-MB468, HepG2, 
Caco-2, A549 and Beas2B respectively (results at 24 and 48 hours of 
incubation are presented in Figure 7, SI). In all cases the aptamers 
without the primer sequence demonstrated to be more toxic to the 
cells.  
 
To confirm the observed cell activity was only due to AC3 and not any 
external DNA, a cell viability assay was performed on Caco-2. With a 
final concentration of 2.5 µM at 24 hours of incubation, the activities 
of the library, alongside AC3 in linear form and a scrambled 
oligonucleotide were explored. The results presented in Table 3 (in 
SI), demonstrated that both the library and scrambled 
oligonucleotide are not active. The linear form of AC3 is mildly active 
(79% viable cells) when compared to the high activity presented by 
the circular form (29% of viable cells). This indicates the observed 
activity is due to AC3 structure and not to the presence of external 
DNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 Cell viability results at 72 hours of incubation with aptamers at 2.5 µM 
final concentration. The results represent the mean ± SEM of 2 independent 
experiments. The p-value for AC3 treatment relative to TBHP show for A549: 
p ˂ 0.00005; Hepg2: p ˂ 0.0005; MCF7: p ˂ 0.0001; MDA-MB468: p ˂ 0.005; 
U2OS: p ˂ 0.0005; Caco-2: p ˂ 0.001 and Beas2B: p ˃ 0.05. 
 
SPR studies showed AC3 and L3 had lower KD in respect to C3-P and 
L3-P). AC3 achieved the lowest KD indicating the strongest binding.  
 
From these studies, aptamer AC3 has demonstrated to be the most 
active. AC3 is a circular aptamer therefore the 5’and 3’ ends are 
ligated, potential conformation could involve the formation of 2 
loops. A few questions arose: would AC3 stand plasma degradation? 
Would AC3 enter the cells and modulate SIRT1 producing an effect? 
Our initial cell-based studies indicate a possible yes to all these 
questions. A set of assays were performed to study in more detail the 
characteristics and effect of AC3. 
 
3.5 Plasma stability of AC3  
 
DNA oligonucleotides have an in vitro half-life in plasma of up to 60 
minutes45. Circularisation can potentially protect an aptamer from 
degradation in plasma. AC3 was tested in human plasma for 
degradation. Stability assays were carried out by incubating 1 µM of 
AC3 with human plasma for up to 24 hours. We analysed the 
outcome via HPLC-UV. The test samples were run on a C18 column 
with absorption monitored at 260 nm. Our studies indicate that 
human plasma eluted between 0.50 to 2.50 minutes. AC3 eluted at 
4.07 minutes as showed in Figure 3A. The samples of human plasma 
plus AC3 showed there is no matrix interference between the 
analytes. We used the retention time of 4.07 minutes for monitoring 
the degradation of the aptamer. As showed in Figure 3 B, 96.3% of 
AC3 is still remaining at 15 minutes. This lowers to 69.0% at 2 hours 
and 62.7% at 24 hours. This nearly 63% of intact circular AC3 
indicates the circular form is very stable. 
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Fig. 3 Stability of AC3 in human plasma up to 24 hours monitored by HPLC-
UV. (A) Comparison of human plasma elution time with AC3. (B) Degradation 
of AC3 in human plasma as a function of time. 
 
3.6 Cell internalisation of AC3  
 
To study the location of AC3’s recognition and binding to SIRT1, 
fluorescence microscopy was used. The cells were incubated with 
AC3 labelled with FAM for a period of 72 hours. The cells were dosed 
with a low concentration of AC3 to avoid cell death, this depended 
on their IC50. To localise SIRT1 in the cell, a primary antibody was used 
coupled with a Texas Red labelled secondary antibody.  The DNA in 
the nuclei was localised using DAPI (AC3 untreated cells are 
presented in Fig 16 and 17, SI). In Figure 4, the overlap of the 
emissions of AC3, SIRT1 and the nuclei are presented (AC3 treated 
cell images for only DAPI and SIRT1 localisation are presented in Fig 
18 to 21, SI). The cells treated with AC3 showed co-localisation with 
SIRT1 confirming the binding. Interestingly, there was no observable 
fluorescence signal on the control cells Beas2B when treated with 
AC3. This could be due to the difference in expression levels of SIRT1 
in respect to the malignant cell lines or to the intrinsic nature of this 
cell line. Fluorescence microscopy studies showed AC3 was 
internalised and was co-localised with SIRT1 in our cancerous cell 
panel. This demonstrates that AC3 has crossed the lipid bilayer of the 
living cells and was recruited to its target.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 Fluorescence microscopy analysis of AC3 binding to SIRT1 enzyme and 
nuclei localisation. AC3-FAM (green-yellow), nuclei (DAPI, blue) and SIRT1 
(Texas Red, red). Overlap of images can produced alterations in the colour 
results such as yellow produced by overlap of red and green, magenta 
produced by red and blue and cyan produced by green and blue. (A) A549, 
scale 100 µm. (B) HepG2 (augmentation in Fig 20, SI. (C) Caco2, scale 200 µm. 
(D) U2OS, scale 200 µm. (E) MCF7, scale 20 µm. (F) MCF7 zoomed. (G) 
MDAMB-468, scale 100 µm. (H) Beas2B, scale 200 µm. Fluorescence intensity 
was measured by LUMIStar Luminometer Microplate Readers as: green ex. 
495 nm, em. 509 nm; blue ex. 359 nm, em. 461 nm and red ex. 596 nm, em. 
615 nm. The results represent the mean ± SEM of two different experiments 
performed  twice. Images were taken at a magnification of 100X in a Cytation 
3.  
 
 
3.7 Catalytic activity characterisation of AC3 towards SIRT1 and 
effect on cell viability  
 
The activity of AC3 was tested on the same panel of cells as described 
before using Fluor de Lys SIRT1 kit. Our results, as showed in Table 4, 
indicate that AC3 increases the activity of SIRT1 in all the tested 
cancerous cell lines. At a concentration of 1 µM, it showed an 
increase fold activity of 1.7 for A549, 2.1 for HepG2, 1.4 for both 
MDA-MB468 and MCF7, 2.7 for Caco-2 and 1.8 for U2OS. It is 
noticeable that AC3 has not increased activity of SIRT1 in Beas2B. 
Thus, AC3 appears to discriminate between cancer cells and non-
cancerous cells, Beas2B. This is an interesting feature on Beas2B, AC3 
seemed to not interact with these cells, maybe due to the lack of 
SIRT1 expression, which is also accompanied by a lack of SIRT1 
activity and cell death. Resveratrol entered this cell line, produced 
cell death and increased SIRT’1 activity. Resveratrol has been shown 
to have several targets within a cell 67 and maybe both effects on 
enhancing catalytic and cell death activities could be due to an earlier 
and/or alternative pathways. Nevertheless it is remarkable AC3 has 
demonstrating activity only on the cancer cells of our panel; and that 
stimulation of SIRT1 activity is relevant to induce cancer death 68. 
 
Table 4 Fold activity of SIRT1 in cells for AC3. 
 SIRT1 fold activitya 
 A549 HepG2 MDAM
B-468 
MCF7 Caco-2 U2OS Beas2
B 
AC3 1.0 
µM 
1.70 
±0.08 
2.07 
±0.01 
1.42 
±0.05 
1.44 
±0.05 
2.66 
±0.19 
1.83 
±0.14 
1.05 
±0.05 
AC3 0.5 
µM 
1.39 
±0.00 
1.41 
±0.04 
1.18 
±0.05 
0.98 
±0.06 
1.48 
±0.15 
1.26 
±0.02 
1.09 
±0.02 
AC3 0.25 
µM 
1.19 
±0.01 
1.16 
±0.01 
1.03 
±0.05 
0.87 
±0.06 
1.15 
±0.13 
0.87 
±0.05 
1.01 
±0.00 
Resverat
rol 100 
µM 
1.74 
±0.09 
1.90 
±0.08 
1.40 
±0.05 
1.04 
±0.11 
2.86 
±0.10 
1.78 
±0.12 
1.78 
±0.07 
Nicotina
mide 
100 µM 
0.81 
±0.11 
0.82 
±0.01 
0.79 
±0.10 
0.75 
±0.01 
0.93 
±0.02 
0.79 
±0.04 
0.70 
±0.03 
a Fluor de Lys SIRT1 kit assay; values represent mean values with standard deviation () 
of two experiments and data normalised to control (SIRT1/Cell + water). A549: p ˂ 
0.0005. Hepg2: p ˂ 0.0001. MCF7: p ˂ 0.001. MDA-MB468: p ˂ 0.001. U2OS: p ˂ 0.001. 
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Caco-2: p ˂ 0.00001. Beas2B: p ˃ 0.05. Nicotinamide was used as negative control as it 
is an inhibitor of SIRT1 therefore no increment in SIRT1 catalytic activity was observed. 
 
Though these values are very similar to the ones obtained by 
resveratrol at 100µM, the concentration of this polyphenolic 
compound proved to be toxic on all cell lines used in this study, 
demonstrating no discrimination between cancer and non-cancerous 
cells. This incremental activity of SIRT1 in the assessed cancer cells, 
was also accompanied by a reduction of the cell viability. Further 
analyses to determine the effect of AC3 at lower concentrations 
during the first 24 hours demonstrated the stimulation of SIRT1 
induced cell death on cancer cells, as shown in Table 5.  
 
Table 5 Percentage of cell viability at 24 hours of incubation.  
  % cell viability at 24ha 
  AC3 Resveratrol 
Cell line  0.25µM 0.50µM 1.00µM 100µM 
A549 78.06 ±0.11 73.01 ±0.06 22.51 ±0.03 6.79 ±0.01 
HepG2 66.96 ±0.01 46.04 ±0.01 8.70 ±0.05 6.04 ±0.01 
MCF-7 69.10 ±0.01 62.93 ±0.02 14.07 ±0.01 4.41 ±0.01 
U2OS 80.48 ±0.05 54.56 ±0.01 16.42 ±0.07 8.50 ±0.02 
MDA-
MB468 76.51 ±0.02 35.77 ±0.04 13.21 ±0.04 7.04 ±0.01 
Caco-2 83.63 ±0.08 49.23 ±0.05 11.55 ±0.01 12.07 ±0.01 
Beas2B 88.31 ±0.03 77.72 ±0.02 86.89 ±0.06 8.86 ±0.01 
     
Cell viability, MTT assay; values represent mean values with standard deviation () of 
two experiments and data normalised to control (Cell + water). A549: p ˂ 0.0005. 
Hepg2: p ˂ 0.0001. MCF7: p ˂ 0.001. MDA-MB468: p ˂ 0.001. U2OS: p ˂ 0.001. Caco-2: 
p ˂ 0.00001. Beas2B: p ˃ 0.05. 
 
At 1.0 μM of AC3, the cell death on A549, MCF7, U2OS, MDA-MB468, 
A549, HepG2 and Caco-2 was in the range of 75- 91%. On the non-
cancerous cells Beas2B, AC3 did not increase SIRT1’s catalytic activity 
for more than 10% and did not substantially affect viability of these 
cells either as 90% of the cell population was still viable after 24 
hours. It is important to notice that resveratrol at 100 µM showed to 
be toxic on the cancerous and non-cancerous cells. Further studies 
to obtain inhibition of growth, provided IC50 values as: 0.32 µM (SD: 
0.05) for A549, 0.20 µM (SD: 0.01) for HepG2, 0.14 µM (SD: 0.02) for 
MCF7, 0.10 µM (SD: 0.01) for MDA-MB468, 0.06µM (SD: 0.01) for 
U2OS, and 0.26 µM (SD: 0.09) for Caco-2 (Figures 8 to 15, SI). 
4. Conclusions 
SIRT1 has many functions; the molecular pathway for SIRT1’s 
anticancer activity might be extremely complex and dependent on 
the cell type. A study on BRCA1 mutant cancer cells showed the use 
of resveratrol restored the activity of SIRT1 and produced inhibition 
of surviving stimulating apoptosis69. A study on APCmin/+ mice by 
Firestein et al70 showed that overexpression of SIRT1 reduces colon 
cancer formation, this appeared to be the result of SIRT1 
deacetylating β-catenin and promoting the oncogenic form to be 
localised in the cytoplasm. 
 
p53 regulates positively SIRT1 transcription though in a negative loop 
p53’s inactivation could reduce the expression of SIRT1, which would 
then increase p53’s activity71. It appears this response would depend 
on the catalytic activity of SIRT1, as only overexpression of 
catalytically active SIRT1 removed p53 acetylation. Another form of 
regulation on p53 by SIRT1, relies on deacetylating p300, a histone 
acetyltransferase of p53 72. Similar negative feedback loops have 
been found, in vitro, on FOXO3a, FOXL2 and E2F1, that can act as 
tumour suppressors in some situations71, 72. Other mechanisms of 
action might be possible for SIRT1, as it interacts with many 
autophagy proteins regulating this process65, 66, 70-73.  
 
SIRT1 plays an important role in DNA damage response and genome 
integrity by maintaining proper chromatin structure and DNA 
damage repair foci formation. Given SIRT1 activity is NAD+ 
dependent, which itself is metabolism dependent, over activity of 
SIRT1 can deplete or skew the energy resources of cancer cells 
abrogating the energy metabolism of malignant cells leading to cell 
death.  
 
In our results, AC3 did not over-activate SIRT1 in non-malignant cells 
indicating that in physiological conditions of normal cells, energy 
metabolism will remain unaffected. It is likely that difference in 
metabolic demands in different types of malignant cells can account 
for the difference in SIRT1 activation and suppression. In order to 
dissect the mechanism of SIRT1 induced cell death, energy 
metabolism of malignant cells, DNA damage and NFκB pathway will 
need to be analysed with AC3 treatment of control and malignant 
cells as further work.  
 
SIRT1 is the most studied of the seven mammalian sirtuins74. 
Modulation of SIRT1 by small ligands such as resveratrol, which might 
not be sufficiently selective, produce unwanted cell death when 
tested in vitro. Using SELEX we developed an extremely selective 
ligand against SIRT1.  
 
In this manuscript, we demonstrate two types of aptamer selection, 
linear and circular. From our results, AC3 a circular aptamer, stood 
up as the best performing aptamer for inducing SIRT1 activity and 
performing anticancer action. 
 
Our aptamer, was produced in vitro using a modified library, we 
characterised the biophysical interactions between AC3 and SIRT1. 
AC3 was recruited to intracellular SIRT1, confirmed by co-
localisation. AC3 has shown anticancer activity for several models of 
cancer including lung (A549), colon (Caco-2), the liver (HepG2), 
osteosarcoma (U2OS) and breast cancer models (MCF-7 and MDA-
MB468). The most interesting feature is that AC3 was non-toxic on 
the non-cancerous cell line Beas2B, implying it might be safe to non-
cancerous tissue. Stability studies also showed AC3 to resist the 
degradation of plasma enzymes up to 24 hours.  
 
In conclusion, using SELEX methodology we have produced an 
aptamer which is: a) selective for SIRT1, b) enters the living cells and 
interacts with SIRT1, c) is stable upon enzymatic attack, d) active on 
cancer cells, e) the mode of action is through activation of SIRT1 and 
f) is safe on non-cancerous cells. A pharmacological activation of 
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SIRT1 enhanced cell death suggesting a tumour suppressive function. 
The complex SIRT1-aptamer identified in this study may be used in 
the future for cancer treatment or biological evaluation of SIRT1.  
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